Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
head and neck cancer
Biotech
Ultimovacs cancer vaccine fails again, enters last chance saloon
The third flop, this time in head and neck cancer, leaves UV1 with one shot at salvation before the biotech reaches the end of its cash runway.
Nick Paul Taylor
Aug 6, 2024 4:14am
Immutep regains pep as cancer subgroup data show path forward
Jul 12, 2024 9:35am
Merck KGaA drops xevinapant with ph. 3 trial headed for failure
Jun 25, 2024 8:50am
Merus cancer bispecific lives up to investors' expectations
May 24, 2024 8:53am
Calliditas' cancer trial misses primary goal, hits on survival
May 7, 2024 6:39am
Ultimovacs lays off 40% in wake of cancer vaccine's phase 2 fail
Apr 17, 2024 8:22am
